HBOT is FDA-cleared for severe, life-threatening anemia, where it raises plasma-dissolved oxygen up to 1200% and can keep organs functioning at hemoglobin as low as 2 to 3 g/dL. That is an emergency bridge, not a treatment for the anemia itself. For chronic anemia, including iron-deficiency, HBOT has no established role. It is one of many conditions studied alongside HBOT, and the split between emergency and chronic use is the whole story.
The distinction that runs through this topic is between treating anemia and compensating for it. Treating anemia means raising red blood cell count or hemoglobin by fixing the cause. Compensating for it acutely means keeping tissue oxygenated despite low hemoglobin, which is what HBOT does in an emergency. Blurring those two is where most of the confusion comes from.
Can HBOT treat anemia?
No. HBOT does not raise hemoglobin or stimulate meaningful red blood cell production, so it does not treat anemia in any lasting sense. What it does is dissolve extra oxygen directly into blood plasma, bypassing hemoglobin entirely. In a genuine emergency that plasma-dissolved oxygen can carry a patient through a crisis, but the underlying anemia is unchanged when the session ends.
Normal blood carries about 20 mL of oxygen per 100 mL, almost all bound to hemoglobin, with only about 0.3 mL dissolved in plasma at ordinary atmospheric pressure. At 2.0 to 3.0 ATA breathing 100% oxygen, plasma-dissolved oxygen rises to roughly 6 mL per 100 mL. When hemoglobin has collapsed, that plasma oxygen alone can be enough to sustain organs, which is the scientific basis for emergency HBOT in anemia.1
increase in plasma-dissolved oxygen with HBOT versus breathing air, the mechanism behind its FDA-cleared use as a bridge in severe anemia
Van Meter, 2005, Undersea Hyperb Med
When is HBOT used for severe anemia?
HBOT is used for severe anemia only in emergencies, when hemoglobin has fallen to life-threatening levels and transfusion is unavailable or refused. The classic case is a patient who declines blood on religious grounds, such as a Jehovah’s Witness, or one for whom compatible blood cannot be found. Here HBOT buys time for the body’s own red cell production, or for a donor, while it functions as temporary life support.
Published case reports document patients surviving at hemoglobin as low as 2 to 3 g/dL, against a normal of 12 to 17 g/dL, with adjunctive HBOT.2,3 In Van Meter’s 2005 systematic review, a series of 26 patients with exceptionally severe blood-loss anemia and class IV shock had roughly 70% overall survival with adjunctive HBOT, and the therapy was well tolerated.1 These are rare, high-acuity situations managed in hospital, not an outpatient anemia treatment.
overall survival in 26 patients with exceptionally severe blood-loss anemia and class IV shock given adjunctive HBOT
Van Meter, 2005, Undersea Hyperb Med
Does HBOT help chronic or iron-deficiency anemia?
No. For the common chronic anemias, including iron deficiency, vitamin B12 or folate deficiency, anemia of chronic disease, and anemia of chronic kidney disease, HBOT has no established therapeutic role. These are treated by fixing the cause: iron replacement, B12 or folate, erythropoiesis-stimulating agents, or managing the underlying disease. HBOT would address none of those and does not stimulate erythropoiesis in a clinically useful way.
The most effective interventions depend entirely on the type of anemia. Iron-deficiency anemia responds to oral or IV iron. B12 deficiency responds to supplementation or injections. Anemia of chronic disease is managed by treating the underlying condition, and anemia of chronic kidney disease often responds to erythropoiesis-stimulating agents plus iron. None of these call for HBOT. When HBOT is not clearly indicated, our page on alternatives to HBOT is a useful comparison.
Should you fix anemia before starting HBOT for another condition?
Yes. If you are pursuing HBOT for an approved indication such as wound healing, radiation injury, or osteomyelitis and you also have anemia, correcting the anemia first can improve the result. HBOT augments plasma-dissolved oxygen, but total oxygen delivery still depends heavily on hemoglobin, so severe anemia blunts the therapy you are paying for. Getting hemoglobin to at least 10 to 11 g/dL before starting is a reasonable target.
Iron matters beyond oxygen carriage: it is a cofactor in collagen synthesis and in the oxidative killing of bacteria by immune cells, two processes central to how HBOT promotes healing. An iron-deficient patient may respond poorly to HBOT’s wound-healing effects even when the HBOT is delivered correctly. This is especially relevant in diabetic patients treated for foot ulcers and in cancer patients receiving HBOT for radiation injury, who often carry treatment-related anemia. Because oxygen delivery and immune function are linked, hemoglobin optimization also supports the pathways discussed on our HBOT and the immune system page.
Is HBOT safe in sickle cell disease?
HBOT is not standard therapy for sickle cell disease and carries specific concerns, so it is used only as a rescue measure in select acute cases with specialist oversight. In an acute vaso-occlusive crisis, improving oxygenation can in principle reduce sickling, and some case reports describe improvement in acute chest syndrome, the leading cause of death in sickle cell disease, with HBOT.
The caution is that a hyperoxic environment may worsen reperfusion injury through reactive oxygen species in some tissues, and current sickle cell guidelines do not recommend HBOT as standard care. If it is considered at all during acute chest syndrome, it is a last resort in a monitored setting, with the treating hematologist central to the decision. Patients with sickle cell disease should never pursue HBOT for general wellness. Anemia is also worth watching during very long HBOT courses of 60 or more sessions, where mild reductions in red cell counts have been reported, so periodic hemoglobin checks are sensible in patients who are already borderline.
| Anemia type | Does HBOT help? | First-line treatment |
|---|---|---|
| Severe acute blood-loss (transfusion unavailable) | Yes, as an emergency bridge only | Transfusion; HBOT if not possible |
| Iron-deficiency anemia | No | Oral or IV iron |
| B12 / folate deficiency | No | B12 or folate replacement |
| Anemia of chronic kidney disease | No | Erythropoiesis-stimulating agents plus iron |
| Sickle cell acute chest syndrome | Investigational rescue only | Guideline-based crisis care; specialist-led |
Can HBOT raise my hemoglobin level?
No. HBOT does not meaningfully raise hemoglobin the way treating the cause of anemia does. It increases plasma-dissolved oxygen, bypassing hemoglobin, which is not the same as increasing red blood cell count or hemoglobin concentration.1 In practical terms, HBOT compensates for severe anemia acutely in an emergency; it does not treat it. If your hemoglobin is low, the effective step is identifying and correcting the cause with your physician.
I have anemia and fatigue. Would HBOT help my energy?
If fatigue is driven by anemia, treating the anemia at its source will help far more than HBOT, which is not evidence-based for anemia-related fatigue. Iron-deficiency and B12 deficiency, two of the most common and correctable causes, respond to supplementation.4 If fatigue persists after anemia is corrected, that is a separate clinical question worth investigating rather than a reason to try HBOT.
Is HBOT used when chemotherapy causes anemia?
Not for the anemia itself. HBOT is sometimes used in cancer patients for radiation injury or wound healing, and those patients often have treatment-related anemia, but the anemia is managed with erythropoiesis-stimulating agents, iron, or transfusion. Some chemotherapy agents, notably bleomycin and doxorubicin, also interact with high-oxygen environments, so any HBOT in cancer patients requires careful oncology coordination.
Sources
- Van Meter KW. “A systematic review of the application of hyperbaric oxygen in the treatment of severe anemia: an evidence-based approach.” Undersea and Hyperbaric Medicine. 2005;32(1):61-83. PMID: 15796315
- Graffeo C, Dishong W. “Severe blood loss anemia in a Jehovah’s Witness treated with adjunctive hyperbaric oxygen therapy.” American Journal of Emergency Medicine. 2013;31(4):756.e3-4. DOI: 10.1016/j.ajem.2012.11.013
- Johnson-Arbor K, Verstraete R. “Use of hyperbaric oxygenation as an adjunctive treatment for severe pernicious anaemia in a bloodless medicine patient.” BMJ Case Reports. 2021;14(2):e240619. DOI: 10.1136/bcr-2020-240619
- Undersea and Hyperbaric Medical Society. “Hyperbaric Oxygen Therapy Indications” (Exceptional Blood Loss Anemia). uhms.org
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
